About US
Contact us
-
Should FDA's standards enforcement be blamed for drug shortages?A House committee report blames FDA oversight for the current epidemic of drug shortages. Rep. Darrell Issa, chairman of the House Oversight Committee, complains that warning letters increased as Pres2012/6/18
-
Regeneron stock falls on new AMD treatment studyRegeneron ($REGN), which makes the new wet AMD treatment Eylea, saw its stock falter after a small drugmaker unveiled data from a study testing its AMD treatment in combination with Eylea rival Lucent2012/6/15
-
Who'll be the biggest drugmaker of them all?Who's ready for the latest Big Pharma line-up? Prepare for some big changes: Pfizer ($PFE) will lose its first-up position in a few years to Novartis ($NVS), EvaluatePharma figures, as Sanofi ($SNY) a2012/6/15
-
Drugmakers warn German pricing is killing innovationAs economies have wilted in Europe, Germany has been all about austerity and how that is the only way to cure the E.U.'s financial woes. But the backlash from drugmakers to German drug pricing has bec2012/6/14
-
Merck plots FDA app as sleep drug aces new trialArmed with new Phase III data on its potential sleep drug suvorexant, Merck ($MRK) plans to ask FDA to approve the new product later this year. One big selling point: 90% of patients didn't feel sleep2012/6/14
-
Supreme Court to put Amgen shareholders' class action on trialTwo types of shareholder lawsuits. Two significant developments that promise to affect future shareholder suits. On the one hand, the U.S. Supreme Court has agreed to weigh a class-action suit against2012/6/13
-
Expect a bump to GSK's Human Genome offer, but not a big oneInvestors and analysts alike expect GlaxoSmithKline ($GSK) to increase its bid for Human Genome Sciences ($HGSI), but not by much, Bloomberg reports. GSK probably will raise its $2.6 billion, $13-per-2012/6/13
-
FDA approves Roche's pricey new Herceptin partner, PerjetaRoche ($RHHBY) has added another targeted breast cancer drug to its oncology quiver. The FDA approved its new treatment for HER2-positive disease, pertuzumab, now dubbed Perjeta. It's a potential bloc2012/6/12
-
China now carries a big compulsory-licensing stickDrugmakers can count compulsory licensing among the new pitfalls of China's huge-and-growing drug market. Thanks to amended intellectual property laws, the Chinese government can now force generic dru2012/6/12
-
GSK extends $2.6 billion bid for Human Genome SciencesGlaxoSmithKline ($GSK) said it would and now it has. It extended its $2.6 billion hostile bid for shares of its partner Human Genome Sciences ($HGSI) by three weeks. The original offer fromGSKof $132012/6/11